The Hemoglobinopathies drugs in development market research report provides comprehensive information on the therapeutics under development for Hemoglobinopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemoglobinopathies. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemoglobinopathies and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Hemoglobinopathies by seven companies/universities/institutes. The top development phase for Hemoglobinopathies is discovery with three drugs in that stage. The Hemoglobinopathies pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Hemoglobinopathies pipeline products market are: Gamida Cell, Bellicum Pharmaceuticals and Daiichi Sankyo.
The key targets in the Hemoglobinopathies pipeline products market include Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1), Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98), and Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98).
The key mechanisms of action in the Hemoglobinopathies pipeline product include Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Inhibitor with one drug in Discovery. The Hemoglobinopathies pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Hemoglobinopathies pipeline products market including Gene Therapy, and Small Molecule.
Hemoglobinopathies overview
Hemoglobinopathy is a group of disorders in which there is abnormal production or structure of the hemoglobin molecule. It is passed down through families (inherited). This group of disorders includes hemoglobin C disease, hemoglobin S-C disease, sickle cell anemia, and thalassemias. Some hemoglobinopathies result in anemias that are severe in patients who are homozygous but mild in those who are heterozygous. Some patients are compound heterozygotes for 2 different hemoglobinopathies and have anemia of varying severity.
For a complete picture of Hemoglobinopathies’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
